Written by Paria Lajevardi and Chrystal Moulton. Polycystic ovary syndrome (PCOS) is a complex hormonal and metabolic condition that can affect insulin sensitivity, reproductive health, and overall well-being. Research suggests that lifestyle changes, particularly regular exercise, along with supplements such as inositol, N-acetylcysteine (NAC), vitamin D, magnesium, and omega-3 fatty acids, may help improve certain metabolic and reproductive symptoms. 

Polycystic Ovary Syndrome (PCOS), also known as Polyendocrine Metabolic Ovarian Syndrome (PMOS), is the most common endocrinologic disorder affecting women of reproductive age.¹ PCOS is marked by varying combinations of ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology, with insulin resistance and hyperinsulinemia commonly occurring but not required for diagnosis.¹ PCOS is associated with a wide range of physical and mental complications, including menstrual irregularities, infertility, increased burden of cardiometabolic risk factors, and anxiety. Despite an estimated global prevalence of approximately 11–13%, the pathophysiology of PCOS is not completely understood, which is why some estimates suggest that up to 70% of affected individuals remain undiagnosed.¹

PCOS is influenced by multiple factors, including genetic, epigenetic, and environmental. Studies have suggested that the disorder has a heritability of 60%-70%, involving multiple genes and pathways related to insulin signaling, sex hormone function, and metabolic regulation.¹ A central feature in many cases is insulin resistance, which leads to hyperinsulinemia. Elevated insulin levels increase the sensitization of theca cells to luteinizing hormone, promoting theca cell androgen production and disrupting normal follicular development.¹ This creates a feedback loop where hyperinsulinemia and androgen excess reinforce each other, which leads to ovarian dysfunction and metabolic imbalance. However, not all individuals with insulin resistance have PCOS, and not all individuals with PCOS are insulin-resistant, indicating that additional factors are likely at play.¹

Clinical management of PCOS focuses on reducing symptoms while improving metabolic and reproductive function, as there is currently no cure. Diagnosis is often based on the Rotterdam Criteria, which requires at least two of the three conditions to be present: ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology.¹ However, these criteria are not universal, which makes diagnosis difficult. First-line interventions include lifestyle modifications such as diet, which have been shown to improve ovulatory dysfunction.¹ Pharmacologic treatments include combined hormonal contraceptives to regulate menstrual cycles and reduce androgen levels, along with medications such as letrozole or clomiphene citrate for infertility. Metformin is also commonly used to improve insulin sensitivity and reduce glucose production; however, its effectiveness varies by patient and is known to cause gastrointestinal side effects.¹ Due to lack of clinical response to existing therapies and their associated side effects, there is a growing interest in alternative insulin-sensitizing strategies, including supplements such as inositol and N-acetylcysteine.

Inositol and PCOS 

Inositol is a naturally occurring sugar-alcohol found in plants and animals that is readily absorbed by the intestine. The compound plays an important role in intracellular signaling and physical development.² As a secondary messenger in the insulin signaling pathways, inositol helps regulate glucose uptake and many other reproductive processes.³

Inositol occurs in nine stereoisomeric forms, but Myo-inositol (MI) and D-chiro-inositol (DCI) are the forms most frequently studied and used in PCOS supplements.⁴ MI is the most common form in the human body, accounting for around 99% of the inositol present in the ovaries. MI supports follicle-stimulating hormone (FSH) signaling, oocyte maturation, follicular development, and ovarian function. In contrast, DCI is produced from MI through an insulin-dependent enzyme called epimerase; it mainly promotes glycogen synthesis and insulin-mediated glucose metabolism.⁵ In women with PCOS, defects in insulin signaling disrupt the normal balance between these two isomers. While insulin-resistant tissues show a reduced response to insulin, the ovaries remain highly sensitive to insulin. This is known as the “ovarian paradox,” which causes excessive conversion of MI to DCI in the ovaries, reducing the MI available for normal follicular development and contributing to impaired ovulation.^3,5 Because MI and DCI regulate different aspects of metabolic and reproductive function, supplementation has been investigated for possible effects on insulin-related measures and markers of ovarian function.

Clinical studies have suggested that inositol supplementation can improve both the metabolic and reproductive manifestations of PCOS. A 2024 systematic review found low certainty that inositol may improve insulin resistance by lowering fasting insulin levels.⁴ In terms of reproductive outcomes, MI supplementation has been associated with improved menstrual regularity, and DCI has been linked to higher ovulation rates.⁴ In one randomized clinical trial, MI restored spontaneous ovulation in around 65% of participants compared with 50% among women treated with metformin, while also leading to fewer gastrointestinal side effects.⁵ Some studies have reported improvements in selected metabolic, hormonal, and reproductive measures with combined MI and DCI supplementation, such as formulations using a 40:1 ratio.^4,5

Despite these findings, current evidence is not enough to recommend inositol as a universal replacement for existing therapies. Many clinical trials have been limited by small sample sizes, short follow-up periods, varying supplement formulations, and inconsistent MI ratios, making direct comparisons difficult and reducing confidence in the overall evidence.^4,5 Inositol has shown limited effects on weight loss and androgen levels; it is well tolerated and has few side effects compared to many popular medications, such as metformin.⁴ Thus, while more research is needed, inositol is a promising adjunctive therapy for improving the symptoms of women with PCOS.

N-acetyl cysteine and PCOS 

Known for its well-established safety profile, N-acetyl cysteine (NAC) is a mucolytic drug that liquefies bronchial secretions.⁶ In recent years, it has also gained attention as a potential insulin-sensitizing therapy for women with PCOS. At higher doses, NAC increases the cellular levels of glutathione (GSH), one of the body’s most important intracellular antioxidants. By doing so, NAC protects insulin receptors from oxidative damage, thus improving insulin signaling and the body’s response to glucose. Apart from its insulin-sensitizing properties, NAC exhibits antioxidant, anti-inflammatory, and anti-apoptotic effects, reducing inflammation and improving antioxidant defenses. These properties may help induce ovulation and menstruation beyond their effects on insulin alone.⁷

Clinical studies have suggested that NAC improved many metabolic and reproductive outcomes in women with PCOS, especially among insulin-resistant groups. In hyperinsulinemic patients, NAC significantly increased insulin sensitivity.⁶ However, little benefit was seen in women with normal insulin levels, suggesting that NAC treatment is more effective in patients who are metabolically compromised. Improvements in insulin resistance have been associated with a reduction in androgen levels.⁶ Additionally, several studies have shown improved menstrual regularity following NAC supplementation, especially for women who are resistant to clomiphene citrate (CC), a first-line ovulation induction medication. NAC given to CC resistant women significantly decreased androgen levels while improving insulin secretion and ovulation.^7,8

In one small trial, NAC and metformin produced comparable improvements in BMI, hirsutism, fasting insulin, HOMA-IR, free testosterone, and menstrual irregularity. However, NAC has been shown to provide additional benefits by lowering total cholesterol and LDL cholesterol, while metformin has only been shown to reduce total cholesterol significantly.⁹ In one small pilot study of women with PCOS undergoing ICSI, combining NAC with metformin did not consistently provide additional hormonal or metabolic benefits compared with the individual interventions.¹⁰ Additionally, combination therapy with NAC, myo-inositol, and folic acid has been associated with improved ovulation rates in women with PCOS regardless of whether they have insulin resistance.¹¹

Despite these positive findings, many limitations prevent NAC from being considered a standard treatment for PCOS. Most clinical trials have involved small sample sizes and short treatment durations, making the long-term efficacy of NAC uncertain. There has also been significant variation in dosing and treatment length, which has limited the ability to establish standardized recommendations. These varied findings highlight the complex pathophysiology of PCOS.¹² Furthermore, improving a single metabolic pathway may not reverse the hormonal abnormalities causing the disorder. While more research is still needed to determine optimal dosage and treatment duration, NAC has an excellent safety profile with few reported side effects, making it a promising adjunctive therapy, particularly for women with insulin resistance or clomiphene-resistant infertility.⁸

Vitamin D and PCOS 

Vitamin D is an essential vitamin best known for its role in bone health, but growing evidence suggests it may also contribute to glucose metabolism, insulin signaling, and ovarian function. Vitamin D also exhibits anti-inflammatory and antioxidant properties that reduce oxidative stress and may help improve insulin resistance, making it a potential supplement for women with PCOS.¹³ Vitamin D receptors (VDRs) and the enzymes responsible for activating Vitamin D are present in pancreatic β-cells and ovarian tissue, along with other insulin-sensitive organs. Within pancreatic β-cells, vitamin D regulates calcium concentrations required for normal insulin secretion and increases insulin sensitivity.¹³ Within ovarian tissue, vitamin D influences follicular development and ovarian apoptosis, suggesting a direct role in reproductive function. Although genetic differences in VDR variants may affect responses to supplementation, vitamin D deficiency has consistently been associated with PCOS, making it a potential contributor to both metabolic and reproductive dysfunction.¹⁴

Clinical studies suggest that correcting vitamin D deficiency can improve many metabolic abnormalities associated with PCOS; however, the scale of these benefits varies across studies.^13,14,15 A systematic review and meta-analysis of 11 randomized controlled trials involving 601 women with PCOS found that vitamin D supplementation significantly improved insulin resistance, especially when administered as daily doses below 4,000 IU rather than intermittent high doses.¹⁶ Vitamin D supplementation combined with other supplements such as calcium and omega-3 led to additional benefits, including lower fasting blood glucose, improved insulin sensitivity, and increased serum 25(OH)D levels, thereby correcting vitamin D deficiency.¹⁶ Despite these positive findings, improvements in lipid metabolism and androgen concentrations have been inconsistent across studies.^14,17

While vitamin D appears promising, it should not be considered a standalone treatment for insulin resistance or PCOS. Although supplementation consistently corrects Vitamin D deficiency, its effects on insulin resistance, diabetes prevention, reproductive hormones, and body composition remain mixed.¹³ Some randomized trials have found improved pancreatic β-cell function and glucose metabolism, but no significant improvements in HOMA-IR, QUICKI, androgen levels, or visceral fat.¹⁸ This suggests that short-term supplementation may improve glucose metabolism before producing measurable changes in insulin sensitivity.¹⁸ Additionally, individual responses vary with baseline vitamin D status, obesity, genetic variation, and the severity of insulin resistance.^13,14 Currently, vitamin D appears to be most beneficial for women with documented deficiency rather than universally effective for all patients with PCOS.¹⁷ Current evidence supports vitamin D supplementation as a safe adjunctive therapy that can improve metabolic health when deficiency is present, but larger, long-term randomized controlled trials are needed to determine optimal dosing and clarify its role in managing insulin resistance in PCOS.

Magnesium and PCOS 

Magnesium is an essential mineral involved in over 300 enzymatic reactions, such as glucose metabolism, insulin signaling, and hormone regulation.¹⁹ Magnesium acts as a cofactor for enzymes involved in glucose transport and insulin secretion, so inadequate magnesium levels can impair insulin signaling and lead to insulin resistance. Given this important function, subclinical magnesium deficiency has been proposed as a contributing factor to the metabolic abnormalities observed in PCOS.²⁰ Magnesium is also known for its anti-inflammatory and antioxidant effects, which help reduce oxidative stress and can improve insulin sensitivity. In addition to these roles, magnesium is involved in regulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It may indirectly benefit reproductive health by improving sleep quality, reducing cortisol levels, and promoting overall metabolic homeostasis.¹⁹

Clinical evidence regarding magnesium supplementation in women with PCOS has shown mixed results. Many randomized controlled trials have reported improvements in metabolic and inflammatory markers when magnesium was administered alongside other nutrients. One study that studied magnesium and vitamin E supplementation showed improved glycemic control, lipid profile, and ovarian function, along with reduced hirsutism.¹⁹ Another study involving magnesium and zinc resulted in increased total antioxidant capacity and reduced hs-CRP and inflammation.¹⁹ Similarly, a study involving magnesium, zinc, calcium, and vitamin D led to the reductions in hirsutism, hs-CRP, and malondialdehyde, while increasing total antioxidant capacity.¹⁹ Despite these positive findings, because magnesium was taken alongside other supplements with anti-inflammatory properties, more research is required to determine how much of the benefit came from magnesium alone.¹⁹

While magnesium cannot be considered a standalone treatment for PCOS, correcting magnesium deficiency can improve metabolic health in women with an insufficient magnesium status. Small sample sizes and short intervention periods limit existing studies.²¹ Additionally, most clinical trials have used magnesium oxide, a form of magnesium with relatively poor absorption.²⁰ Magnesium glycinate, which combines magnesium with the amino acid glycine, is a commonly preferred supplement due to its high absorption, gentleness on the digestive tract, and low likelihood of causing diarrhea.^20,21 Thus, while magnesium glycinate may be more suitable for long-term supplementation, direct clinical evidence supporting its use specifically in women with PCOS remains limited.²¹ Larger randomized controlled trials are needed to determine whether magnesium glycinate provides superior improvements in insulin sensitivity, hormonal balance, and reproductive outcomes.

 

Form	Best for	Notes
Magnesium glycinate	Sleep, stress, hormone support	Preferred for fertility support due to tolerability
Magnesium citrate	General supplementation, constipation	Good absorption, but may cause loose stools
Magnesium malate	Fatigue, muscle discomfort	Supports energy metabolism
Magnesium threonate	Brain/cognitive effects	More expensive
Magnesium oxide	Constipation	Must have adequate stomach acid or taken with a meal, otherwise poorly absorbed

Exercise and PCOS 

Lifestyle modification is an essential part of PCOS management. Regular physical activity is recommended as a first-line intervention because it improves both metabolic and reproductive health.²² Unlike supplements and pharmacological therapies, exercise targets multiple underlying mechanisms of PCOS simultaneously and has shown significant benefits even without visible weight loss. Exercise improves insulin sensitivity, which in turn may reduce androgen excess by making muscles more responsive to insulin.²² As hyperandrogenism improves, many women also experience reproductive benefits, including menstrual regularity and ovulation frequency. Exercise is also known to improve blood pressure and body composition, which results in better overall cardiovascular fitness and reduced cardiovascular disease risk.²² Beyond these physical benefits, exercise also provides mental health benefits by improving mood, psychological well-being, and quality of life; this is especially helpful for women with PCOS who have high rates of depression and anxiety.²² Adults with PCOS should generally aim for 150–300 minutes of moderate-intensity activity or 75–150 minutes of vigorous-intensity activity weekly, together with muscle-strengthening activities on two nonconsecutive days.²²

The benefits of exercise in PCOS have consistently been studied across systematic reviews and meta-analyses. A systematic review studying the effects of exercise alone, without dietary intervention, showed that 12 to 24 weeks of moderate-intensity aerobic and resistance exercise decreased insulin resistance by 9-30%, reduced body weight by 4.5-10%, and improved ovulation and fertility.²³ Additional studies have shown significant improvements in cardiovascular health, including reduced blood pressure, improved cholesterol levels, and aerobic fitness.²³ A meta-analysis of 14 studies involving 617 women with PCOS found reductions in fasting insulin, waist circumference, and systolic blood pressure, as well as improvements in lipid profiles and reproductive function.²⁴ Another systematic review and meta-analysis of 18 randomized controlled trials found that exercise significantly reduces fasting insulin, HOMA-IR, and abdominal fat, and improves cardiovascular and metabolic health, as well as overall quality of life.²⁵ Aerobic exercise has the strongest supporting evidence, but resistance training has also shown metabolic benefits. Studies suggest that consistency and long-term adherence are more important than the specific type of exercise performed.^23,25

While there is strong evidence supporting exercise as an effective treatment for PCOS, many limitations exist. Many clinical studies have small sample sizes and vary in exercise type, intensity, duration, and measurable outcomes, making direct comparisons difficult.^24,25 Therefore, the overall quality of evidence for some reproductive outcomes is low, and larger, randomized controlled trials are needed to determine the optimal exercise needed for different patients with PCOS. Additionally, while exercise with dietary intervention is recommended in clinical practice, current evidence has not conclusively shown that adding exercise to dietary modification yields greater metabolic improvements than dietary intervention alone, largely due to the limited number of high-quality comparative studies.²⁵ Despite these limitations, the consistent metabolic, reproductive, and mental improvements that exercise has shown make it one of the most effective non-pharmacological strategies for managing PCOS.²²

Omega-3 Fatty Acids and PCOS

 Omega-3 fatty acids are polyunsaturated fatty acids that have gained attention as a potential adjunctive therapy for PCOS because of their anti-inflammatory and insulin-sensitizing effects. EPA and DHA are long-chain omega-3 fatty acids found primarily in oily fish and marine oils. These fatty acids have been shown to influence many metabolic pathways involved in PCOS.²⁶ Proposed mechanisms include increased production of anti-inflammatory lipid mediators, activation of GPR120 receptors, and increased adiponectin levels, a hormone that regulates glucose metabolism and insulin sensitivity.²⁶ Omega-3 fatty acids also improve lipid metabolism by reducing triglycerides, increasing fatty acid oxidation, reducing liver fat production, and decreasing VLDL synthesis.²⁶ Through these mechanisms, omega-3 supplementation can help improve insulin sensitivity, reduce cardiovascular risk, and alleviate some of the metabolic dysfunction associated with PCOS.

Clinical evidence has shown that omega-3 supplementation can provide meaningful metabolic benefits for women with PCOS. A systematic review and meta-analysis of nine randomized controlled trials involving 591 women found that supplementation significantly reduced insulin resistance (measured by HOMA-IR), lowered total cholesterol and triglyceride concentrations, and increased adiponectin levels.²⁷ A larger review of 21 clinical studies also showed similar benefits, including improvements in insulin sensitivity, fasting insulin levels, blood glucose regulation, and lipid profiles, as well as reductions in triglyceride and total cholesterol levels.²⁸ Some studies also showed reductions in LDL cholesterol, improvements in menstrual regularity, and increases in sex hormone-binding globulin levels, suggesting that omega-3 supplementation may help improve hormonal balance and reduce hyperandrogenism.^26,28 Additionally, supplementation has been linked to lower oxidative stress and lower inflammatory marker concentrations (e.g., hs-CRP). However, these anti-inflammatory effects have not been observed consistently across all studies.²⁸ It is also important to note that many studies reported improvements in insulin resistance and metabolic health despite little or no significant weight loss, indicating that the benefits of omega-3 fatty acids may not extend to changes in body weight.^26,28

Although current evidence supports omega-3 fatty acids as a promising adjunctive therapy for PCOS, many limitations still exist. Most clinical trials have been short, used small sample sizes, and employed different omega-3 formulations and doses. Therefore, more research is still needed to determine optimal EPA and DHA dosage and determine which PCOS phenotypes benefit most from supplementation.²⁸ Current dietary recommendations encourage consuming fatty fish 1-2 times every week and adopting healthy dietary patterns, such as the Mediterranean diet.²⁸ Overall, omega-3 fatty acids appear to be a safe adjunctive therapy that improves metabolic health and may reduce long-term cardiovascular risk. However, further research is needed to develop standardized treatment recommendations.

Conclusion 

While there is currently no cure for PCOS, research shows that many of its metabolic and reproductive symptoms can be improved through targeted lifestyle changes and supplementation. Regular physical activity, a balanced diet rich in whole foods, adequate sleep, and stress management are core pillars of PCOS care because they address many of the underlying mechanisms that contribute to insulin resistance and hormonal imbalance. For women with nutrient deficiencies, supplements such as myo-inositol, N-acetylcysteine, vitamin D, magnesium, and omega-3 fatty acids can provide support when used alongside these healthy lifestyle habits.

Because people respond differently based on factors such as insulin resistance, vitamin status, and PCOS phenotype, supplementation should be tailored to each person’s needs and discussed with healthcare professionals.

As research continues to evolve, insulin-sensitizing supplements show promise as a complement to conventional treatments and help women take a more active role in managing their health. Choosing high-quality supplements from reputable manufacturers, maintaining consistent healthy habits, and working with a healthcare professional to develop personal treatment plans can help maximize benefits. Supplementation cannot replace medical care, but it can be a valuable tool to improve metabolic health, support reproductive function, and enhance overall quality of life for women living with PCOS.

References:

1. Chan, L., Masini, I., & Pisarska, M. D. (2026). Polyendocrine metabolic ovarian syndrome (PMOS)/polycystic ovary syndrome (PCOS): current and future trends. Journal of Clinical Investigation, 136(12). https://doi.org/10.1172/jci202824
2. Lee, A., & Bedford, M. R. (2016). Inositol – An effective growth promotor? World’s Poultry Science Journal, 72(4), 743–760. https://doi.org/10.1017/s0043933916000660
3. Genazzani, D. (2016). Inositol as putative integrative treatment for PCOS. Reproductive BioMedicine Online, 33(6), 770–780. https://doi.org/10.1016/j.rbmo.2016.08.024
4. Fitz, , Graca, S., Mahalingaiah, S., Liu, J., Lai, L., Butt, A., Armour, M., Rao, V., Naidoo, D., Maunder, A., Yang, G., Vaddiparthi, V., Witchel, S. F., Pena, A., Spritzer, P. M., Li, R., Tay, C., Mousa, A., Teede, H., & Ee, C. (2024). Inositol for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 update of the International Evidence-based PCOS Guidelines. The Journal of Clinical Endocrinology & Metabolism, 109(6), 1630–1655. https://doi.org/10.1210/clinem/dgad762
5. Unfer, Vittorio, Nestler, John E., Kamenov, Zdravko A., Prapas, Nikos, Facchinetti, Fabio, Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials, International Journal of Endocrinology, 2016, 1849162, 12 pages, https://doi.org/10.1155/2016/1849162
6. Fulghesu, (2002). N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertility and Sterility, 77(6), 1128–1135. https://doi.org/10.1016/s0015-0282(02)03133-3
7. Rizk, Y., Bedaiwy, M. A., & Al-Inany, H. G. (2005). N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate–resistant patients with polycystic ovary syndrome. Fertility and Sterility, 83(2), 367–370. https://doi.org/10.1016/j.fertnstert.2004.07.960
8. Mokhtari, , Afsharian, P., Shahhoseini, M., Kalantar, S. M., & Moini, A. (2017). A Review on Various Uses of N-Acetyl Cysteine. Cell Journal, 19(1), 11–17. https://doi.org/10.22074/cellj.2016.4872
9. Oner, , & Muderris, I. I. (2011). Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 159(1), 127–131. https://doi.org/10.1016/j.ejogrb.2011.07.005

10. Cheraghi, , Soleimani Mehranjani, M., Shariatzadeh, M. A., Nasr Esfahani, M. H., & Ebrahimi, (2014). Co-administration of metformin and N-acetyl cysteine fails to improve clinical manifestations in PCOS individuals undergoing ICSI. International Journal of Fertility & Sterility, 8(2), 119–128. PMCID: PMC4107684.
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC4107684/Sacchinelli, A., Venturella, R., Lico, D., Di Cello, A., Lucia, A., Rania, E., Cirillo, R., & Zullo, F. (2014). The Efficacy of Inositol and N-Acetyl Cysteine Administration (Ovaric HP) in Improving the Ovarian Function in Infertile Women with PCOS with or without Insulin Obstetrics and Gynecology International, 2014, 1–5. https://doi.org/10.1155/2014/141020
12. Köse, A., & Nazıroğlu, M. (2015). N-acetyl cysteine reduces oxidative toxicity, apoptosis, and calcium entry through TRPV1 channels in the neutrophils of patients with polycystic ovary syndrome. Free Radical Research, 49(3), 338–346. https://doi.org/10.3109/10715762.2015.1006214
13. Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C., & Muñoz-Torres, M. (2021). Mechanisms Involved in the Relationship between Vitamin D and Insulin Resistance: Impact on Clinical Practice. Nutrients, 13(10), 3491. https://doi.org/10.3390/nu13103491
14. Mohan, , Haider, R., Hajar Fakhor, Hina, F., Kumar, V., Jawed, A., Majumder, K., Ayaz, A., Priyanka Mohan Lal, Tejwaney, U., Ram, N., & Saka Kazeem. (2023). Vitamin D and polycystic ovary syndrome (PCOS): a review. Annals of Medicine and Surgery, 85(7), 3506–3511. https://doi.org/10.1097/ms9.0000000000000879
15. Patra, K., Nasrat, H., Goswami, B., & Jain, A. (2012). Vitamin D as a predictor of insulin resistance in Polycystic Ovarian Syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 6(3), 146–149. https://doi.org/10.1016/j.dsx.2012.09.006
16. Łagowska, , Bajerska, J., & Jamka, M. (2018). The Role of Vitamin D Oral Supplementation in Insulin Resistance in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients, 10(11), 1637. https://doi.org/10.3390/nu10111637
17. Selimoglu, H., Duran, C., Kiyici, S., Ersoy, C., Guclu, M., Ozkaya, G., Tuncel, E., Erturk, E., & Imamoglu, (2009). The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. Journal of Endocrinological Investigation, 33(4), 234–238. https://doi.org/10.1007/bf03345785
18. Seyyed Abootorabi, , Ayremlou, P., Behroozi-Lak, T., & Nourisaeidlou, S. (2017). The effect of vitamin D supplementation on insulin resistance, visceral fat and adiponectin in vitamin D deficient women with polycystic ovary syndrome: a randomized placebo-controlled trial. Gynecological Endocrinology, 34(6), 489–494. https://doi.org/10.1080/09513590.2017.1418311
19. Fernandez, (2026, March 29). Best Magnesium for Fertility: Forms, Dosing & Evidence (2026). Lifespan Method. https://lifespanmethod.com/best-magnesium-supplements-for-fertility/ 
20. Porri, , Biesalski, H. K., Limitone, A., Bertuzzo, L., & Cena, H. (2021). Effect of Magnesium Supplementation on women’s Health and well-being. NFS Journal, 23, 30–36. https://doi.org/10.1016/j.nfs.2021.03.003
21. Mahsa Gholizadeh-Moghaddam, Hatav Ghasemi Tehrani, Askari, , Mahsima Jaripur, Clark, & Mohammad Hossein Rouhani. (2022). Effect of magnesium supplementation in improving hyperandrogenism, hirsutism, and sleep quality in women with polycystic ovary syndrome: A randomized, placebo-controlled clinical trial. Health Science Reports, 6(1). https://doi.org/10.1002/hsr2.1013
22. Teede, J., et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. European Journal of Endocrinology, 189(2), G43–G64. https://doi.org/10.1093/ejendo/lvad096
23. Harrison, C. L., Lombard, C. B., Moran, L. J., & Teede, H. J. (2010). Exercise therapy in polycystic ovary syndrome: a systematic Human Reproduction Update, 17(2), 171–183. https://academic.oup.com/humupd/article-abstract/17/2/171/692261
24. Benham, J. L., Yamamoto, J. M., Friedenreich, C. M., Rabi, D. M., & Sigal, R. J. (2018). Role of exercise training in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Obesity, 8(4), 275–284. https://doi.org/10.1111/cob.12258
25. Kite, , Lahart, I. M., Afzal, I., Broom, D. R., Randeva, H., Kyrou, I., & Brown, J. E. (2019). Exercise, or exercise and diet for the management of polycystic ovary syndrome: a systematic review and meta-analysis. Systematic Reviews, 8(1). https://doi.org/10.1186/s13643-019-0962-3
26. Albardan, , Carine Platat, & Nishan Sudheera Kalupahana. (2024). Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome. Nutrients, 16(17), 2961–2961. https://doi.org/10.3390/nu16172961
27. Yang, , Zeng, L., Bao, T., & Ge, J. (2018). Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: a systematic review and meta-analysis. Reproductive Biology and Endocrinology, 16(1). https://doi.org/10.1186/s12958-018-0346-x
28. Melo, , Silva, T., Silva, T., Freitas, J., Sacramento, J., Vazquez, M., & Araujo, E. (2022). Omega-3 supplementation in the treatment of polycystic ovary syndrome (PCOS) – a review of clinical trials and cohort. Endocrine Regulations, 56(1), 66–79. https://doi.org/10.2478/enr-2022-0008